Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations

Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia

2001 • 5,189 citations

Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis

2000 • 2,700 citations

Matrix Metalloproteinases: Biologic Activity and Clinical Implications

2000 • 1,533 citations

MMP-9 Supplied by Bone Marrow–Derived Cells Contributes to Skin Carcinogenesis

2000 • 1,306 citations

Matrix metalloproteinases: they're not just for matrix anymore!

2001 • 1,257 citations

In vivo visualization of gene expression using magnetic resonance imaging

2000 • 1,143 citations

Effects of Angiogenesis Inhibitors on Multistage Carcinogenesis in Mice

1999 • 990 citations

Design and Therapeutic Application of Matrix Metalloproteinase Inhibitors

1999 • 965 citations

The Stromal Proteinase MMP3/Stromelysin-1 Promotes Mammary Carcinogenesis

1999 • 916 citations

Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia

2000 • 897 citations

Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention

1999 • 840 citations

Development of Matrix Metalloproteinase Inhibitors in Cancer Therapy

2001 • 788 citations

In vivo molecular target assessment of matrix metalloproteinase inhibition

2001 • 730 citations

Matrix metalloproteinases: multifunctional contributors to tumor progression

2000 • 639 citations

Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin

1997 • 612 citations

Antisense RNA-Induced Reduction in Murine TIMP Levels Confers Oncogenicity on Swiss 3T3 Cells

1989 • 459 citations

Marimastat as First-Line Therapy for Patients With Unresectable Pancreatic Cancer: A Randomized Trial

2001 • 432 citations

Elevated matrix metalloprotease and angiostatin levels in integrin α1 knockout mice cause reduced tumor vascularization

2000 • 388 citations

Matrix metalloproteinases and TIMPs

2000 • 379 citations

Effects of inhibitors of plasminogen activator, serine proteinases, and collagenase IV on the invasion of basement membranes by metastatic cells

1988 • 352 citations

Inhibition by human recombinant tissue inhibitor of metalloproteinases of human amnion invasion and lung colonization by murine B16-F10 melanoma cells.

1988 • 312 citations

Dynamics of matrix turnover during pathologic remodeling of the extracellular matrix.

1996 • 295 citations

In Vivo Evidence That the Stromelysin-3 Metalloproteinase Contributes in a Paracrine Manner to Epithelial Cell Malignancy

1998 • 290 citations

Inhibition of Collagenolytic Activity and Metastasis of Tumor Cells by a Recombinant Human Tissue Inhibitor of Metalloproteinases

1990 • 233 citations

Suppression of the Tumorigenic and Metastatic Abilities of Murine B16-F10 Melanoma Cells In Vivo by the Overexpression of the Tissue Inhibitor of the Metalloproteinases-1

1994 • 221 citations

Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies.

1998 • 211 citations

Effect of Matrix Metalloproteinase Inhibitor Batimastat on Breast Cancer Regrowth and Metastasis in Athymic Mice

1995 • 190 citations

Effect of tissue inhibitor of the matrix metalloproteinases-2 expression on the growth and spontaneous metastasis of a human melanoma cell line.

1994 • 168 citations

Ongoing trials with matrix metalloproteinase inhibitors

2000 • 168 citations

The matrix metalloproteinase matrilysin influences early-stage mammary tumorigenesis.

1998 • 162 citations

Overexpression of metalloproteinase inhibitor in B16F10 cells does not affect extravasation but reduces tumor growth.

1994 • 160 citations

Expression and Prognostic Significance of Metalloproteinases and Their Tissue Inhibitors in Patients With Small-Cell Lung Cancer

1999 • 158 citations

Matrix Metalloproteinase Inhibitor COL-3 in the Treatment of AIDS-Related Kaposi's Sarcoma: A Phase I AIDS Malignancy Consortium Study

2002 • 153 citations

Low plasma levels of matrix metalloproteinase 9 permit increased tumor angiogenesis

2002 • 151 citations

Collagenase Expression in Transgenic Mouse Skin Causes Hyperkeratosis and Acanthosis and Increases Susceptibility to Tumorigenesis

1995 • 141 citations

Protease inhibitors: Role and potential therapeutic use in human cancer

1994 • 134 citations

Hydroxamate-type matrix metalloproteinase inhibitor batimastat promotes liver metastasis.

2001 • 131 citations

Marimastat in Patients With Advanced Pancreatic Cancer

1999 • 112 citations

Inhibition of SV40 T antigen-induced hepatocellular carcinoma in TIMP-1 transgenic mice.

1996 • 99 citations

Differing effects of endogenous and synthetic inhibitors of metalloproteinases on intestinal tumorigenesis

1998 • 98 citations

Matrix metalloproteinases as emerging targets in anticancer therapy: status and prospects

2000 • 77 citations

Marimastat in recurrent colorectal cancer: exploratory evaluation of biological activity by measurement of carcinoembryonic antigen

1999 • 71 citations

Clinical imaging of cancer metastasis

2000 • 35 citations

The Effects of Sustained Elevated Levels of Circulating Tissue Inhibitor of Metalloproteinases‐1 on the Development of Breast Cancer in Mice

1999 • 20 citations

Introduction

2000 • 12 citations

Latest FDA approvals for dentistry.

1999 • 12 citations

Tumour marker levels during marimastat therapy

1996 • 10 citations